Biosketch

Dr. Robert Danner directs the Continuous Renal Replacement Therapy Service and heads the Functional Genomics Facility in the Clinical Center’s Critical Care Medicine Department at the National Institutes of Health.

Currently he also is a special consultant to the Food and Drug Administration and a member of the editorial advisory board of Journal of Infectious Diseases. He has served as a member of Food and Drug Administration’s Anti-Infective Drug Products Advisory Committee, the editorial board of Critical Care Medicine, and the Society of Critical Care Medicine’s Continuing Education Committee.

Dr. Danner’s research focuses on septic shock and multiple organ failure, nitric oxide, and functional genomics of critical illness and injury.

He received an undergraduate degree in biology from Johns Hopkins University and a medical degree from Cornell University. He then completed residency training at New York Hospital’s Cornell University Medical Center. His fellowship training was in critical care medicine and infectious diseases at NIH and at Children’s National Medical Center.

Dr. Danner was appointed as a senior investigator in the CC’s Critical Care Medicine Department in 1988. Since 1999, he has also been a clinical professor of medicine at George Washington University Medical Center.

Honors and Awards

Society of Critical Care Medicine presidential citation for outstanding contributions, 2007; Consumer’s Research Council of America, top physician, 2006; NIH Director’s Award, 2006; U.S. Public Health Service crisis response service award, Gulf Coast hurricanes, 2005; USPHS Outstanding Unit Citation, 2003; USPHS Outstanding Service Medal (clinical medicine and research), 2000; American Federation for Clinical Research Henry Christian Award for abstract in immunology, 1999 and 1998; USPHS Achievement Medal, 1997; USPHS Commendation Medal, 1994 and 1990; Society of Critical Care Medicine Education Scholarship Award, 1993; The AFCR Henry Christian Award poster presentation, 1991; Alpha Omega Alpha, 1979; Phi Beta Kappa, 1975.

Selected Publications

Journal Articles

Pawliczak R, Logun C, Madara P, Barb J, Suffredini AF, Munson PJ, Danner RL, Shelhamer JH. “The influence of Interferon gamma (IFN-γ) on gene expression in normal human bronchial epithelial cells: Modulation of IFN-γ effects Dexamethasone.” Physiological Genomics, 23:28-45, 2005.

Eichacker PQ, Danner RL, Suffredini AF, Cui X, Natanson C. “Reassuring recombinant human activated protein C for Sepsis: Time for a new randomized controlled trial.” [Editorial]. Critical Care Medicine, 33:2426-2428, 2005.

Cui X, Zhang J, Ma P, Myers DE, Goldberg IG, Sittler KJ, Barb JJ, Munson PJ, Cintron AP, McCoy JP, Wang S, Danner RL. “cGMP-independent nitric oxide signaling and regulation of the cell cycle.” BMC Genomic, 6:151-169, 2005.

Talwar S, Munson PJ, Barb J, Fiuza C, Cintron AP, Logun C, Tropea M, Khan S, Reda D, Shelhamer JH, Danner RL,Suffredini AF. “Gene Expression profiling of peripheral blood leukocytes after endotoxin challenge in humans.” Physiological Genomics, 25(2):203-215, 2006.

Solomon S, Cui X, Gerstenberger E, Danner RL, Fitz Y, Banks SM, Natanson C, Eichacker PQ, “Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection.” Journal of Infectious Diseases, 193(5):634-644, 2006.

Wang S, Zhang J, Theel S, Barb JJ, Munson PJ, Danner RL. “Nitric Oxide activation of Erk ½ regulates the stability and translation of mRNA transcripts containing CU-rich elements.” Nucleic Acids Research, 34(10):3044-3056, 2006.

Kalil AC, Sevransky J, Myers D, Esposito C, Vandivier RW, Eichacker P, Sulsa G, Solomon SB, Csako G, Costello R, Sittler KJ, Banks S, Natanson C, Danner RL. “Preclinical trial of L-arginine alone or with N-acetylcysteine in septic shock.” Critical Care Medicine, 34(11):2719-2728, 2006.

Eichaker PQ, Natanson C, Danner RL. “Surviving sepsis-practice guidelines, marketing, campaigns, and Eli Lilly.” New England Journal of Medicine, 355(16):1640-1642, 2006.

Zhang J, Wang S, Kern S, Cui X, Danner RL. “Nitric oxide down-regulates polo-like kinase 1 through a proximal promoter cell cycle gene homology region.” Journal of Biological Chemistry, 282(2):1003-1009, 2006.

Ptasinka A, Wang S, Zhang J, Danner RL. “Nitric Oxide activation of peroxisone proliferator activated receptor gamma through a p38 MAPK signaling pathway.” FASEB Journal, 21:950-961, 2007.

Raghavachari N, Xu X, Harris A, Villagra J, Logun C, Barb J, Solomon MA, Suffredini AF, Danner RL, Munson PJ, Kato G, Morris SM, Gladwin MT. “ Amplified expressions profiling of platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease.” Circulation, 115(2):1551-1562, 2007.